Chemosensitization of prostate cancer by modulating Bcl-2 family proteins

Current Drug Targets

Volumn 11, Issue 6, 2010, Pages 699-707

  Karnak, David ^a   Xu, Liang ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Apoptosis; Bcl 2; BH3 mimetics; Chemoresistance; Mcl 1; Prostate cancer

Indexed keywords

ABT-263; AT-101; DNA; DOCETAXEL; GEMCITABINE; MESSENGER RNA; MICRORNA; NANOPARTICLE; NUCLEIC ACID; OBATOCLAX; OBLIMERSEN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CHEMOSENSITIZATION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; HUMAN; LUNG CANCER; PROSTATE CANCER; RNA INTERFERENCE; SOLID TUMOR;

ANIMALS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 77953496226     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791170888     Document Type: Article

References (112)

1. Assikis VJ, Simons JW. Novel therapeutic strategies for androgen- independent prostate cancer: An update. Semin Oncol 2004; 31(2 Suppl 4): 26-32.
2. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998; 160(4): 1220-9.
3. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116(2): 205-19.
4. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002; 1(2): 111-21.
5. Kroemer G. Mitochondrial control of apoptosis: an overview. Biochem Soc Symp 1999; 66: 1-15.
6. Goodin S, Rao KV, DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 2002; 7(4): 360-70.
7. DiPaola RS, Patel J, Rafi MM. Targeting apoptosis in prostate cancer. Hematol Oncol Clin North Am 2001; 15(3): 509-24.
8. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 3(1): 17-22.
9. Ponder BA. Cancer genetics. Nature 2001; 411: 336-341.
10. Gjertsen BT, Logothetis CJ, McDonnell TJ. Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer Metastasis Rev 1999; 17: 345-51
11. Xu L, Frederik P, Pirollo KF, et al. Self-assembly of a virus- mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum Gene Ther 2002; 13(3): 469-81.
12. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Ann Rev Immun 1998; 16: 395-419.
13. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997; 34(4 Suppl 5): 9-19.
14. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387(6635): 773-6.
15. Reed JC, Jurgensmeier JM, Matsuyama S. Bcl-2 family proteins and mitochondria. Biochim Biophys Acta 1998; 1366(1-2): 127-37.
16. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999; 59(7 Suppl): 1693s-700s.
17. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008; 27 Suppl 1: S149-57.
18. Chan SL, Yu VC. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin Exp Pharmacol Physiol 2004; 31(3): 119-28.
19. Giam M, Huang DC, Bouillet P. BH3-only proteins and their roles in programmed cell death. Oncogene 2008; 27 Suppl 1: S128-36.
20. Tan TT, Degenhardt K, Nelson DA, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005; 7(3): 227-38.
21. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26(9): 1324-37.
22. Lee EC, Tenniswood M. Programmed cell death and survival pathways in prostate cancer cells. Arch Androl 2004; 50(1): 27-32.
23. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001; 11(11): S22-6.
24. Konopleva M, Zhao S, Hu W, et al. The anti-apoptotic genes Bcl- X(L) and Bcl-2 are over-expressed and contribute to chemo- resistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 2002; 118(2): 521-34.
25. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996; 2(2): 389-98.
26. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148(5): 1567-76.
27. Beale PJ, Rogers P, Boxall F, Sharp SY, Kelland LR. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 2000; 82(2): 436-40.
28. Del Bufalo D, Biroccio A, Trisciuoglio D, et al. Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. Eur J Cancer 2002; 38(18): 2455-62.
29. DiPaola RS, Aisner J. Overcoming bcl-2- and p53-mediated resis- tance in prostate cancer. Sem Oncol 1999; 26(1 Suppl 2): 112-6.
30. Ferlini C, Raspaglio G, Mozzetti S, et al. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 2003; 64(1): 51-8.
31. Reed JC. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv Pharmacol 1997; 41: 501-32.
32. Grad JM, Zeng XR, Boise LH. Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr Opin Oncol 2000; 12(6): 543-9.
33. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA. Bcl-xL in prostate cancer cells: effects of overexpression and down- regulation on chemosensitivity. Cancer Res 2000; 60(21): 6052-60.
34. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381(6580): 335-41.
35. Gleave M, Miyake H, Zangemeister-Wittke U, Jansen B. Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev 2002; 21(1): 79-92.
36. Miyake H, Monia BP, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 2000; 86(6): 855-62.
37. Gleave M, Nelson C, Chi K. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer. Curr Drug Targets 2003; 4(3): 209-21.
38. Reed JC. Bcl-2 family proteins and the hormonal control of cell life and death in normalcy and neoplasia. Vitam Hormones 1997; 53: 99-138.
39. Han J, Goldstein LA, Gastman BR, Rabinovitz A, Rabinowich H. Disruption of Mcl-1.Bim complex in granzyme B-mediated mitochondrial apoptosis. J Biol Chem 2005; 280(16): 16383-92.
40. O'Driscoll L, Cronin D, Kennedy SM, et al. Expression and prognostic relevance of Mcl-1 in breast cancer. Anticancer Res 2004; 24(2A): 473-82.
41. Johnston JB, Paul JT, Neufeld NJ, et al. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk Lymphoma 2004; 45(10): 2017-27.
42. Gomez-Bougie P, Bataille R, Amiot M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol 2004; 34(11): 3156-64.
43. Cavarretta IT, Neuwirt H, Zaki MH, et al. Mcl-1 is regulated by IL- 6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv Exp Med Biol 2008; 617: 547-55.
44. Amirghofran Z, Monabati A, Gholijani N. Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer. Pathol Oncol Res 2004; 10(1): 37-41.
45. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 2000; 19(56): 6627-31.
46. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997; 90(3): 1208-16.
47. Bonetti A, Zaninelli M, Leone R, et al. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 1998; 4(10): 2331-6.
48. Heere-Ress E, Thallinger C, Lucas T, et al. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer 2002; 99(1): 29-34.
49. Cronauer MV, Schulz WA, Burchardt T, et al. The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review). Int J Oncol 2003; 23(4): 1095-102.
50. Rago R. Management of hormone-sensitive and hormone- refractory metastatic prostate cancer. Cancer Control 1998; 5(6): 513-21.
51. Rege YD, Rangnekar VM. Molecular therapy intervention prospects in prostate cancer. Curr Pharm Design 2004; 10(5): 523-30.
52. Gutierrez-Puente Y, Zapata-Benavides P, Tari AM, Lopez-Berestein G. Bcl-2-related antisense therapy. Semin Oncol 2002; 29(3 Suppl 11): 71-6.
53. Miyake H, Hara I, Kamidono S, Gleave ME. Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. Int J Urol 2001; 8(7): 337-49.
54. Vilenchik M, Raffo AJ, Benimetskaya L, Shames D, Stein CA. Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. Cancer Res 2002; 62(7): 2175-83.
55. Del Bufalo D, Trisciuoglio D, Scarsella M, Zangemeister-Wittke U, Zupi G. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 2003; 22(52): 8441-7.
56. Gautschi O, Tschopp S, Olie RA, et al. Activity of a novel bcl- 2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Nat Cancer Inst 2001; 93(6): 463-71.
57. Guensberg P, Wacheck V, Lucas T, et al. Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells. Chemotherapy 2002; 48(4): 189-95.
58. Itoh M, Noutomi T, Chiba H, Mizuguchi J. BcI-xL antisense treatment sensitizes Bcl-xL-overexpressing squamous cell carcinoma cells to carboplatin. Oral Oncol 2002; 38(8): 752-6.
59. Simoes-Wust AP, Schurpf T, Hall J, Stahel RA, Zangemeister-Wittke U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res Treat 2002; 76(2): 157-66.
60. Wacheck V, Heere-Ress E, Halaschek-Wiener J, et al. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med 2001; 79(10): 587-93.
61. Patel MP, Masood A, Patel PS, Chanan-Khan AA. Targeting the Bcl-2. Curr Opin Oncol 2009; 21(6): 516-23.
62. Sternberg CN, Dumez H, Van Poppel H, et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration- resistant prostate cancer. Ann Oncol 2009; 20(7): 1264-9.
63. Cheson BD. Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Ther Clin Risk Manag 2007; 3(5): 855-70.
64. Sieghart W, Losert D, Strommer S, et al. Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. J Hepatol 2006; 44(1): 151-7.
65. Zangemeister-Wittke U, Huwiler A. Antisense targeting of Mcl-1 has therapeutic potential in gastric cancer. Cancer Biol Ther 2006; 5(10): 1355-6.
66. Aichberger KJ, Mayerhofer M, Gleixner KV, et al. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 2007; 109(7): 3031-41.
67. Wacheck V, Cejka D, Sieghart W, et al. Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther 2006; 5(10): 1348-54.
68. Yamanaka K, Rocchi P, Miyake H, et al. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 2005; 4(11): 1689-98.
69. Skvara H, Thallinger C, Wacheck V, et al. Mcl-1 blocks radiation- induced apoptosis and inhibits clonogenic cell death. Anticancer Res 2005; 25(4): 2697-703.
70. Schulze-Bergkamen H, Fleischer B, Schuchmann M, et al. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 2006; 6: 232.
71. Hattori Y, Yoshizawa T, Koga K, Maitani Y. NaCl induced high cationic hydroxyethylated cholesterol-based nanoparticle-mediated synthetic small interfering RNA transfer into prostate carcinoma PC-3 cells. Biol Pharm Bull 2008; 31(12): 2294-301.
72. Wei SH, Dong K, Lin F, et al. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol 2008; 62(6): 1055-64.
73. Kessel D, Arroyo AS. Apoptotic and autophagic responses to Bcl-2 inhibition and photodamage. Photochem Photobiol Sci 2007; 6(12): 1290-5.
74. Lin Y, Fukuchi J, Hiipakka RA, Kokontis JM, Xiang J. Up- regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen- independent growth stage. Cell Res 2007; 17(6): 531-6.
75. Cheng TL, Teng CF, Tsai WH, et al. Multitarget therapy of malignant cancers by the head-to-tail tandem array multiple shRNAs expression system. Cancer Gene Ther 2009; 16(6): 516-31.
76. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005; 353(17): 1768-71.
77. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302(1): 1-12.
78. Zhao RC, Zhu YS, Shi Y. New hope for cancer treatment: exploring the distinction between normal adult stem cells and cancer stem cells. Pharmacol Ther 2008; 119(1): 74-82.
79. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27(12): 1788-93.
80. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2008; 17(2): 215-20.
81. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009; 4(8): e6816.
82. Gondi CS, Rao JS. Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol 2009; 220(2): 285-91.
83. Perkel JM. RNAi Therapeutics: A Two-Year Update. Science [special adv. feat.] 2009 Oct. 16.
84. Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001; 44(25): 4313-24.
85. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003; 30(5 Suppl 16): 133-42.
86. Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. PNAS 2000; 97(13): 7124-9.
87. Bae J, Hsu SY, Leo CP, Zell K, Hsueh AJ. Underphosphorylated BAD interacts with diverse antiapoptotic Bcl-2 family proteins to regulate apoptosis. Apoptosis 2001; 6(5): 319-30.
88. Lutz RJ. Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins. Bioch Soc Trans 2000; 28(2): 51-6.
89. Shangary S, Johnson DE. Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 2003; 17(8): 1470-81.
90. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435(7042): 677-81.
91. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67(2): 782-91.
92. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315(5813): 856-9.
93. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT- 737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10(5): 389-99.
94. Lin X, Morgan-Lappe S, Huang X, et al. 'Seed' analysis of off- target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007; 26(27): 3972-9.
95. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10(5): 375-88.
96. Martin AP, Park MA, Mitchell C, et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol 2009; 76(2): 327-41.
97. Lin J, Zheng Z, Li Y, et al. A novel Bcl-XL inhibitor Z36 that induces autophagic cell death in Hela cells. Autophagy 2009; 5(3): 314-20.
98. Etxebarria A, Landeta O, Antonsson B, Basanez G. Regulation of antiapoptotic MCL-1 function by gossypol: mechanistic insights from in vitro reconstituted systems. Biochem Pharmacol 2008; 76(11): 1563-76.
99. Zhang M, Liu H, Guo R, et al. Molecular mechanism of gossypol- induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003; 66(1): 93-103.
100. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/ leukemia-2 proteins. J Med Chem 2003; 46(20): 4259-64.
101. Liu S, Kulp SK, Sugimoto Y, et al. The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. AntiCancer Res 2002; 22(1A): 33-8.
102. Oliver CL, Bauer JA, Wolter KG, et al. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 2004; 10(22): 7757-63.
103. Loberg RD, McGregor N, Ying C, Sargent E, Pienta KJ. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen- independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia 2007; 9(12): 1030-7.
104. Meng Y, Tang W, Dai Y, et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008; 7(7): 2192-202.
105. Xu L, Yang D, Wang S, et al. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 2005; 4(2): 197-205.
106. Kolluri SK, Zhu X, Zhou X, et al. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008; 14(4): 285-98.
107. Lin B, Kolluri SK, Lin F, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004; 116(4): 527-40.
108. Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008; 111(11): 5350-8.
109. Kim KW, Moretti L, Mitchell LR, Jung DK, Lu B. Combined Bcl- 2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non- small cell lung tumor xenograft model. Clin Cancer Res 2009; 15(19): 6096-105.
110. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15(4): 1126-32.
111. Stauffer SR. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737. Curr Top Med Chem 2007; 7(10): 961-5.
112. Vogler M, Weber K, Dinsdale D, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009; 16(7): 1030-9.